Fig. 4

Optical coherence tomography (OCT) images of the representative cases with persistent SRF from the type 1 and type 2 MNV groups. The first case (left column) is of a 74-year-old male with type 1 MNV treated using the treat-and-extend regimen with aflibercept during the 2-year follow-up. The Snellen BCVA was 0.3, and fibrovascular PED and SRF were observed on SD-OCT at baseline. A total 13 times of intravitreal aflibercept injection were administered for 2 years. Although small amount of SRF persisted for 2 years, the Snellen BCVA was improved to 0.5 and apparent atrophic or degenerative change in the outer retina were not observed for 2 years. The second case (right column) is of a 68-year-old female with type 2 MNV treated using the treat-and-extend regimen with aflibercept during the 2-year follow-up. The Snellen BCVA was 0.5, and subretinal MNV, SRF and IRF were observed on SD-OCT at baseline. A total 12 times of intravitreal aflibercept injection were administered for 2 years. The SRF and IRF were subsided after 3-monthly aflibercept intravitreal injections, but SRF recurred at 6 months and persisted. Although persistent SRF was observed, the Snellen BCVA was improved to 0.7 and external limiting membrane and ellipsoid zone were intact at 2 years